BLRX BioLineRx Ltd.

2.26
-0.03  -1%
Previous Close 2.29
Open 2.28
52 Week Low 1.0609
52 Week High 3.3
Market Cap $47,969,472
Shares 21,225,430
Float 21,225,430
Enterprise Value $36,081,255
Volume 617,813
Av. Daily Volume 6,269,125
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
BL-8040 GENESIS
Stem-cell mobilization for autologous transplantation
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Motixafortide
Acute respiratory distress syndrome (ARDS) secondary to COVID-19
Phase 1b
Phase 1b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
AGI-134
Solid tumors
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Motixafortide and Libtayo
First-line pancreatic ductal adenocarcinoma
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Motixafortide (BL-8040) - BLAST
Consolidation treatment for AML cancer patients
Phase 2b
Phase 2b
Phase 2b trial did not meet primary endpoint - November 23, 2020.
BL-8040 in combination with KEYTRUDA
Pancreatic cancer
Phase 2a
Phase 2a
Phase 2a data presented at ESMO December 13, 2019.

Latest News

  1. TEL AVIV, Israel, Nov. 23, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended September 30, 2020 and provides a corporate update.

    Significant events and achievements during the third quarter 2020 and subsequent period:

    • Reported positive results from a pre-planned interim analysis of GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients. The Data Monitoring Committee (DMC) found statistically significant evidence favoring treatment with motixafortide in the primary endpoint, and subsequently issued a recommendation to cease patient enrollment immediately. In…

    TEL AVIV, Israel, Nov. 23, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended September 30, 2020 and provides a corporate update.

    Significant events and achievements during the third quarter 2020 and subsequent period:

    • Reported positive results from a pre-planned interim analysis of GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients. The Data Monitoring Committee (DMC) found statistically significant evidence favoring treatment with motixafortide in the primary endpoint, and subsequently issued a recommendation to cease patient enrollment immediately. In accordance with the DMC's recommendation, study enrollment was completed at 122 patients (instead of 177 as originally planned). SCM is the Company's most efficient path to registration;
    • Announced initiation of Phase 2 investigator-initiated study of motixafortide in combination with LIBTAYO® and chemotherapy in first-line PDAC. The study is being run by Columbia University;
    • Announced initiation of investigator-initiated Phase 1b study, led by Wolfson Medical Center in Holon, Israel, to evaluate motixafortide in patients hospitalized with acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections;
    • Renewed study enrollment in Part of Phase 1/2a trial for AGI-134, which had been temporarily suspended in the second quarter of 2020 due to clinical operating risks associated with the COVID-19 pandemic;
    • Conducted interim analysis for Phase 2b BLAST study in consolidation AML; analysis did not demonstrate statistically significant effect in primary endpoint; DMC recommended not to continue the study.

    "The past several months have been very exciting for BioLineRx, highlighted by the very positive result of the interim analysis of our Phase 3 GENESIS study in stem cell mobilization" stated Philip Serlin, Chief Executive Officer of BioLineRx. "A statistically significant benefit in the primary endpoint was observed by combining motixafortide with the standard of care, G-CSF, leading the DMC to recommend that we cease study enrollment at 122 patients, instead of the 177 originally planned. We look forward to publishing final results of the study in the first half of next year, as we continue to advance motixafortide toward registration.

    "With regard to the Phase 2b BLAST study in consolidation AML, based on the results of the interim analysis, the DMC recommended not to continue the study. Although we are disappointed by this outcome, particularly following the positive results that we previously observed in our Phase 1/2a study of motixafortide with cytarabine in relapsed/refractory AML, we continue to believe in the relevance of CXCR4 as a viable target in other AML treatment lines, such as rr/AML and induction treatment. We will decide on next steps in AML once we've had a chance to review and analyze the unblinded data, including detailed biomarker and subpopulation data, from this study. I would also like to express our gratitude to the University of Halle, as study sponsor, and Dr. Carsten Müller-Tidow, as principal study investigator, as well as the other investigators and the patients who made this important trial possible.

    "Finally, in the coming weeks, we plan to announce full results, including progression free survival (PFS) and overall survival (OS) data, on all study patients from the triple combination arm of our Phase 2a COMBAT/KEYNOTE-202 study in second-line PDAC. We previously shared preliminary positive overall response rate and disease control rate data, on approximately half of the patients enrolled in this study arm, at last year's ESMO IO conference, and we remain optimistic that the combination of motixafortide and KEYTRUDA®, together with chemotherapy, will prove beneficial to survival as well.

    "The significant and growing body of data that we are compiling on motixafortide, including the strikingly positive results of the interim analysis in the GENESIS phase 3 study reported last month, reassure us about the unique characteristics of motixafortide as the best-in-class CXCR4 antagonist, and confirm our belief that this promising compound can potentially serve as the backbone of combination therapies to treat a broad range of solid tumor and hematological cancers," Mr. Serlin concluded.

    Upcoming Expected Milestones

    • Overall final results, including PFS and OS data, from the COMBAT/KEYNOTE-202 Phase 2a triple combination study in second-line PDAC by the end of 2020;
    • Final results from the Phase 3 GENESIS trial in SCM in the first half of 2021;
    • Preliminary results of the Phase 1b study in ARDS in the first half of 2021;
    • Initial results from Part 2 of the Phase 1/2a trial of AGI-134 in solid tumors in the second half of 2021;
    • Data from the Columbia University-initiated study of motixafortide in combination with LIBTAYO® and chemotherapy in first-line PDAC in mid-2022;

    Financial Results for the Quarter Ended September 30, 2020

    Research and development expenses for the three months ended September 30, 2020 were $3.5 million, a decrease of $2.1 million compared to $5.6 million for the comparable period in 2019. The decrease resulted primarily from termination of the BATTLE clinical study for motixafortide in 2019 and from lower expenses associated with the AGI-134 study, as well as a decrease in payroll and related expenses due to a Company-wide salary reduction related to the COVID-19 pandemic carried out in the second and third quarters of 2020. Research and development expenses for the nine months ended September 30, 2020 were $13.5 million, a decrease of $1.7 million, compared to $15.2 million for the nine months ended September 30, 2019. The decrease resulted primarily from lower expenses associated with the motixafortide COMBAT clinical trial and the AGI-134 study, as well as a decrease in payroll and related expenses due to a Company-wide salary reduction related to the COVID-19 pandemic mentioned above.

    Sales and marketing expenses for three months ended September 30, 2020 were $0.3 million, an increase of $0.1 million compared to $0.2 million for the comparable period in 2019. The increase resulted primarily from consultancy services and market research for motixafortide offset by a decrease in payroll and related expenses related to a reduction in headcount. Sales and marketing expenses for the nine months ended September 30, 2020 were $0.7 million, similar to the comparable period in 2019.

    General and administrative expenses for the three months ended September 30, 2020 were $0.9, similar to the comparable period in 2019. General and administrative expenses for the nine months ended September 30, 2020 were $2.8 million, similar to the comparable period in 2019.

    The Company's operating loss for the three months ended September 30, 2020 amounted to $4.6 million, compared to an operating loss of $6.6 million for the comparable period in 2019. The Company's operating loss for the nine months ended September 30, 2020 was $17.1 million, compared to $18.7 million for the comparable period in 2019.

    Non-operating income (expenses) for the three- and nine-month periods ended September 30, 2020 and 2019 primarily relate to fair-value adjustments of warrant liabilities on the Company's balance sheet, offset by warrant offering expenses and issuance expenses of the Company's ATM program.

    Net financial expenses for the three months ended September 30, 2020 amounted to $0.3 million compared to net financial expenses of $0.4 million for the comparable period in 2019. Net financial expenses for both periods primarily relate to interest paid on loans, offset by investment income earned on bank deposits. Net financial expenses for the nine months ended September 30, 2020 amounted to $0.9 million, similar to the comparable period in 2019. Net financial expenses for both periods primarily relate to interest paid on loans, offset by investment income earned on bank deposits.

    The Company's net loss for the three months ended September 30, 2020 amounted to $4.6 million, compared with a net loss of $3.9 million for the comparable period in 2019. The Company's net loss for the nine months ended September 30, 2020 amounted to $18.0 million, compared with a net loss of $15.6 million for the comparable period in 2019.

    The Company held $20.8 million in cash, cash equivalents and short-term bank deposits as of September 30, 2020.

    Net cash used in operating activities was $17.8 million for the nine months ended September 30, 2020, compared with net cash used in operating activities of $17.2 million for the nine months ended September 30, 2019. The $0.6 million increase in net cash used in operating activities during the nine-month period in 2020 was primarily the result of the decrease in accounts payable and accruals in the 2020 period.

    Net cash provided by investing activities was $8.1 million for the nine months ended September 30, 2020, compared to net cash provided by investing activities of $2.1 million for the nine months ended September 30, 2019. The changes in cash flows from investing activities relate primarily to investments in, and maturities of, short-term bank deposits.

    Net cash provided by financing activities was $10.9 million for the nine months ended September 30, 2020, compared to net cash provided by financing activities of $16.6 million for the nine months ended September 30, 2019. The cash flows in 2020 primarily reflect the May and June financings and the net proceeds from the Company's ATM program, offset by repayments of the loan from Kreos Capital. The cash flows in 2019 primarily reflect the underwritten public offering of our ADSs in February 2019, as well as net proceeds from the ATM facility.

    Conference Call and Webcast Information

    BioLineRx will hold a conference call today, November 23, 2020 at 10:00 a.m. EST. To access the conference call, please dial +1-866-744-5399 from the US or +972-3-918-0664 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

    A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx's website. A dial-in replay of the call will be available until November 25, 2020; please dial +1-877-456-0009 from the US or +972-3-925-5929 internationally.

    (Tables follow)

    About BioLineRx

    BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

    The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, and for which positive data in respect of the study's primary endpoint was recently announced from an interim analysis, resulting in early cessation of recruitment. Motixafortide is also being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with MSD.

    BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

    For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

    Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates; BioLineRx's ability to establish and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; risks related to the coronavirus outbreak; and statements as to the impact of the political and security situation in Israel on BioLineRx's business. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2020. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

    Contact:

    Tim McCarthy

    LifeSci Advisors, LLC

    +1-212-915-2564

     

    BioLineRx Ltd.

    CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

    (UNAUDITED)















    December 31,

    September 30,



    2019

    2020



    in USD thousands

    Assets





    CURRENT ASSETS





    Cash and cash equivalents

    5,297

    6,552

    Short-term bank deposits

    22,192

    14,275

    Prepaid expenses

    108

    269

    Other receivables

    613

    327

              Total current assets

    28,210

    21,423







    NON-CURRENT ASSETS





    Property and equipment, net

    1,816

    1,462

    Right-of-use assets, net

    1,650

    1,423

    Intangible assets, net

    21,891

    21,731

              Total non-current assets

    25,357

    24,616

              Total assets

    53,567

    46,039







    Liabilities and equity





    CURRENT LIABILITIES





    Current maturities of long-term loans

    2,692

    2,969

    Accounts payable and accruals:





         Trade

    7,794

    5,933

         Other

    1,280

    1,374

    Lease liabilities

    202

    200

              Total current liabilities

    11,968

    10,476

    NON-CURRENT LIABILITIES





    Warrants

    658

    5,600

    Long-term loans, net of current maturities

    5,799

    3,554

    Lease liabilities

    1,762

    1,601

              Total non-current liabilities

    8,219

    10,755

    COMMITMENTS AND CONTINGENT LIABILITIES





         Total liabilities

    20,187

    21,231







    EQUITY





    Ordinary shares

    4,692

    8,281

    Share premium

    265,938

    271,107

    Capital reserve

    12,132

    12,835

    Other comprehensive loss

    (1,416)

    (1,416)

    Accumulated deficit

    (247,966)

    (265,999)

              Total equity

    33,380

    24,808

              Total liabilities and equity

    53,567

    46,039

         

     

    BioLineRx Ltd.

    CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

    (UNAUDITED)





    Three months ended September 30,

    Nine months ended

    September 30,



    2019

    2020

    2019

    2020



    in USD thousands

    in USD thousands

    RESEARCH AND DEVELOPMENT EXPENSES

    (5,558)

    (3,484)

    (15,252)

    (13,546)

    SALES AND MARKETING EXPENSES

    (201)

    (309)

    (683)

    (666)

    GENERAL AND ADMINISTRATIVE EXPENSES

    (884)

    (856)

    (2,763)

    (2,843)

    OPERATING LOSS

    (6,643)

    (4,649)

    (18,698)

    (17,055)

    NON-OPERATING INCOME (EXPENSES), NET

    3,055

    294

    3,976

    (80)

    FINANCIAL INCOME

    247

    39

    628

    214

    FINANCIAL EXPENSES

    (597)

    (302)

    (1,484)

    (1,112)











    NET LOSS AND COMPREHENSIVE LOSS

    (3,938)

    (4,618)

    (15,578)

    (18,033)













    in USD

    in USD

    LOSS PER ORDINARY SHARE - BASIC AND DILUTED

    (0.03)

    (0.02)

    (0.11)

    (0.08)











    WEIGHTED AVERAGE NUMBER OF SHARES USED IN

    CALCULATION OF LOSS PER ORDINARY SHARE

     

    148,920,707

    296,508,550

    142,527,942

    231,380,969























     



    BioLineRx Ltd.

    CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

    (UNAUDITED)





















    Ordinary Shares

    Share premium

    Capital reserve

    Other

    comprehensive

    loss

    Accumulated deficit

    Total



     

    in USD thousands

    BALANCE AT JANUARY 1, 2019

    3,110

    250,192

    11,955

    (1,416)

    (222,520)

    41,321

    CHANGES FOR NINE MONTHS ENDED SEPTEMBER 30,

    2019:













    Issuance of share capital, net

    1,018

    11,266

    -

    -

    -

    12,284

    Employee stock options exercised

    1

    53

    (53)

    -

    -

    1

    Employee stock options forfeited and expired

    -

    919

    (919)

    -

    -

    -

    Share-based compensation              

    -

    -

    1,170

    -

    -

    1,170

    Comprehensive loss for the period

    -

    -

    -

    -

    (15,578)

    (15,578)

    BALANCE AT SEPTEMBER 30, 2019

    4,129

    262,430

    12,153

    (1,416)

    (238,098)

    39,198

















    Ordinary Shares

    Share premium











    Capital reserve

    Other 

    Comprehensive
    Loss

    Accumulated deficit

    Total



    in USD thousands

    BALANCE AT JANUARY 1, 2020

    4,692

    265,938

    12,132

    (1,416)

    (247,966)

    33,380

    CHANGES FOR NINE MONTHS ENDED SEPTEMBER 30, 2020:













    Issuance of share capital, net

    3,581

    4,754

    -

    -

    -

    8,335

    Employee stock options exercised

    8

    224

    (224)

    -

    -

    8

    Employee stock options forfeited and expired

    -

    191

    (191)

    -

    -

    -

    Share-based compensation              

    -

    -

    1,118

    -

    -

    1,118

    Comprehensive loss for the period

    -

    -

    -

    -

    (18,033)

    (18,033)

    BALANCE AT SEPTEMBER 30, 2020

    8,281

    271,107

    12,835

    (1,416)

    (265,999)

    24,808















     



    BioLineRx Ltd.

    CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

    (UNAUDITED)

     



    Ordinary

    Share

    Capital

    Other

    Comprehensive

    Accumulated





    Shares

    premium

    reserve

    Loss

    deficit

    Total



    in USD thousands

    BALANCE AT JULY 1, 2019

    4,001

    261,522

    11,835

    (1,416)

    (234,160)

    41,782

    CHANGES FOR THREE MONTHS ENDED SEPTEMBER 30, 2019:













    Issuance of share capital, net

    128

    829

    -

    -

    -

    957

    Employee stock options exercised

    -

    26

    (26)

    -

    -

    -

    Employee stock options forfeited and expired

    -

    53

    (53)

    -

    -

    -

    Share-based compensation              

    -

    -

    397

    -

    -

    397

    Comprehensive loss for the period

    -

    -

    -

    -

    (3,938)

    (3,938)

    BALANCE AT SEPTEMBER 30, 2019

    4,129

    262,430

    12,153

    (1,416)

    (238,098)

    39,198

















     

    Ordinary

     

    Share

     

    Capital

    Other

    Comprehensive

     

    Accumulated





    Shares

    premium

    Reserve

    Loss

    deficit

    Total



    in USD thousands

    BALANCE AT JULY 1, 2020

    8,281

    271,107

    12,639

    (1,416)

    (261,381)

    29,230

    CHANGES FOR THREE MONTHS ENDED SEPTEMBER 30, 2020:













    Issuance of share capital, net

    -

    -

    -

    -

    -

    -

    Employee stock options exercised

    -

    -

    -

    -

    -

    -

    Employee stock options forfeited and expired

    -

    -

    -

    -

    -

    -

    Share-based compensation              

    -

    -

    196

    -

    -

    196

    Comprehensive loss for the period

    -

    -

    -

    -

    (4,618)

    (4,618)

    BALANCE AT SEPTEMBER 30, 2020

    8,281

    271,107

    12,835

    (1,416)

    (265,999)

    24,808















     

    BioLineRx Ltd

    CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

    (UNAUDITED)





    Nine months ended September 30,



    2019

    2020



    in USD thousands







    CASH FLOWS - OPERATING ACTIVITIES





    Comprehensive loss for the period

    (15,578)

    (18,033)

    Adjustments required to reflect net cash used in operating activities

     (see appendix below)

    (1,658)

    259







    Net cash used in operating activities

    (17,236)

    (17,774)







    CASH FLOWS - INVESTING ACTIVITIES





    Investments in short-term deposits

    (34,517)

    (28,500)

    Maturities of short-term deposits

    36,637

    36,626

    Purchase of property and equipment

    (54)

    (1)

    Net cash provided by investing activities

    2,066

    8,125







    CASH FLOWS - FINANCING ACTIVITIES





    Issuance of share capital and warrants, net of issuance costs

    16,836

    13,411

    Employee stock options exercised

    1

    8

    Repayments of loans

    (70)

    (2,338)

    Repayments of lease liabilities

    (165)

    (162)

    Net cash provided by financing activities

    16,602

    10,919







    INCREASE IN CASH AND CASH EQUIVALENTS

    1,432

    1,270

    CASH AND CASH EQUIVALENTS - BEGINNING

       OF PERIOD

    3,404

    5,297

    EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS

    49

    (15)

    CASH AND CASH EQUIVALENTS - END OF PERIOD

    4,885

    6,552









     

    BioLineRx Ltd.

    APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

    (UNAUDITED)







    Nine months ended

    September 30,



    2019

    2020



    in USD thousands













    Adjustments required to reflect net cash used in operating activities:





    Income and expenses not involving cash flows:





    Depreciation and amortization

    667

    737

    Long-term prepaid expenses

    (3)

    -







    Exchange differences on cash and cash equivalents

    (49)

    15

    Fair value adjustments of warrants

    (4,429)

    (727)

    Share-based compensation

    1,170

    1,118

    Warrant issuance costs

    417

    593

    Interest and exchange differences on short-term deposits

    (628)

    (209)

    Interest on loans

    512

    370

    Exchange differences on lease liability 

    -

    4



    (2,343)

    1,901







    Changes in operating asset and liability items:





    Decrease in prepaid expenses and other receivables

    265

    125

      Increase (decrease) in accounts payable and accruals

    420

    (1,767)



    685

    (1,642)



    (1,658)

    259













    Supplemental information on interest received in cash

    628

    342







    Supplemental information on interest paid in cash

    782

    671







     

     

    Cision View original content:http://www.prnewswire.com/news-releases/biolinerx-reports-third-quarter-2020-financial-results-and-provides-corporate-update-301178794.html

    SOURCE BioLineRx Ltd.

    View Full Article Hide Full Article
  2. Management to hold a conference call at 10:00 a.m. EST

    TEL AVIV, Israel, Nov. 18, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2020 on Monday, November 23, 2020, before the US markets open.

    The Company will host a conference call on Monday, November 23, 2020 at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software…

    Management to hold a conference call at 10:00 a.m. EST

    TEL AVIV, Israel, Nov. 18, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2020 on Monday, November 23, 2020, before the US markets open.

    The Company will host a conference call on Monday, November 23, 2020 at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

    To dial into the conference call, please dial +1-866-744-5399 from the U.S. or +972-3-918-0664 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx's website. A dial-in replay of the call will be available until November 25, 2020; please dial +1-877-456-0009 from the U.S. or +972-3-925-5929 internationally.

    About BioLineRx

    BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

    The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation. Motixafortide is also being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with MSD, as well as a Phase 2b study in consolidation AML.

    BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

    For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on FacebookTwitter, and LinkedIn.

    Contact: 

    Tim McCarthy 

    LifeSci Advisors, LLC  

    +1-212-915-2564   

     

    or

    Moran Meir  

    LifeSci Advisors, LLC  

    +972-54-476-4945   

     

    Cision View original content:http://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020-301175789.html

    SOURCE BioLineRx Ltd.

    View Full Article Hide Full Article
  3. TEL AVIV, Israel, Nov. 18, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be evaluated in an investigator-initiated clinical trial in patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections.

    The open-label, single-arm, Phase 1b study will be conducted at the Wolfson Medical Center in Holon, Israel, with Dr. Yasmin Maor, Head of the Infectious Disease Unit, as lead investigator.

    "Severe COVID-19 cases, where patients are hospitalized with ARDS and require ventilation, have generated renewed…

    TEL AVIV, Israel, Nov. 18, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be evaluated in an investigator-initiated clinical trial in patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections.

    The open-label, single-arm, Phase 1b study will be conducted at the Wolfson Medical Center in Holon, Israel, with Dr. Yasmin Maor, Head of the Infectious Disease Unit, as lead investigator.

    "Severe COVID-19 cases, where patients are hospitalized with ARDS and require ventilation, have generated renewed interest in the underlying pathology of acute respiratory stress disorder," noted Dr. Maor. "Substantial data is emerging regarding the involvement of neutrophils, neutrophil extracellular traps (NETs), monocytes and macrophages in the development of ARDS secondary to COVID-19 and other viral infections; as well as the key involvement of CXCR4 as a mediator of those cells in the inflamed pulmonary tissue. Based on the scientific data indicating the importance of blocking the CXCR4/CXCL12 axis during ARDS, Motixafortide could be of potential benefit for such patients. COVID-19 case counts are again surging in many parts of the world and addressing ARDS has become a top global health priority."

    The primary endpoint of the study is to assess the safety of Motixafortide in patients with ARDS secondary to COVID-19 and other respiratory viral infections. Respiratory parameters and inflammatory biomarkers will be assessed as exploratory endpoints. Up to 25 patients will be enrolled, with a preliminary analysis planned after ten patients have completed the initial treatment period. Based on the preliminary evaluation, a decision to continue or not will be conducted by Dr. Maor, together with the Company.

    "We believe there is strong scientific rationale for exploring Motixafortide in ARDS, and we are grateful to Dr. Maor for initiating this study," stated Philip Serlin, Chief Executive Officer of BioLineRx. "We have compiled a significant body of data demonstrating Motixafortide's utility as a best-in-class CXCR4 inhibitor and we are eager to evaluate its effectiveness in blunting the cytokine storm that is associated with poor COVID-19 infection outcomes. We look forward to results from the preliminary analysis in the first half of next year. 

    "In parallel, we remain on track to announce full data from our Phase 2a COMBAT/KEYNOTE-202 study in pancreatic cancer, as well as interim results from our Phase 2b BLAST study in AML, by the end of this year," Mr. Serlin concluded.

    About BioLineRx

    BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

    The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, and for which positive data in respect of the study's primary endpoint was recently announced from an interim analysis, resulting in early cessation of recruitment. Motixafortide is also being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with MSD, as well as a Phase 2b study in consolidation AML.

    BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

    For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

    Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates; BioLineRx's ability to establish and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; risks related to the coronavirus outbreak; and statements as to the impact of the political and security situation in Israel on BioLineRx's business. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2020. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law. 

     

    Contact:

    Tim McCarthy

    LifeSci Advisors, LLC

    +1-212-915-2564

    or

    Moran Meir

    LifeSci Advisors, LLC

    +972-54-476-4945

     

     

    Cision View original content:http://www.prnewswire.com/news-releases/biolinerx-announces-initiation-of-phase-1b-clinical-trial-in-patients-with-acute-respiratory-distress-syndrome-ards-secondary-to-covid-19-and-other-respiratory-viral-infections-301175813.html

    SOURCE BioLineRx Ltd.

    View Full Article Hide Full Article
  4. TEL AVIV, Israel, Oct. 30, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.

    At a meeting of the study's independent Data Monitoring Committee (DMC), a planned interim analysis of the study's primary endpoint was conducted independently by the DMC. Based on the statistically significant evidence favoring treatment with motixafortide, the DMC issued a recommendation to the Company that patient enrollment may be ceased immediately, without the need to recruit all 177 patients originally planned…

    TEL AVIV, Israel, Oct. 30, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.

    At a meeting of the study's independent Data Monitoring Committee (DMC), a planned interim analysis of the study's primary endpoint was conducted independently by the DMC. Based on the statistically significant evidence favoring treatment with motixafortide, the DMC issued a recommendation to the Company that patient enrollment may be ceased immediately, without the need to recruit all 177 patients originally planned for the study.

    In accordance with the DMC's recommendation, study enrollment is now complete at 122 patients. Full results for the study, including secondary and exploratory efficacy endpoints, as well as extended safety data, will be announced after the last patient enrolled reaches 100 days of follow-up post-transplantation, which is expected to occur in the first half of 2021.

    "The compelling results of this planned interim analysis are a very significant milestone for our Company, as our SCM program is the Company's most efficient path to registration for motixafortide," stated Philip Serlin, Chief Executive Officer of BioLineRx. "Stem cell mobilization represents a significant unmet medical need in multiple myeloma, as between 50% and 70% of patients are poor mobilizers. We eagerly await the final results of the study, expected in the first half of next year, which we hope will support our goal of changing the treatment paradigm in autologous stem-cell mobilization, thus positioning motixafortide in combination with G-CSF as the new standard of care in this indication."

    The GENESIS trial was initiated in December 2017. GENESIS is a randomized, placebo-controlled, multicenter study, evaluating the safety, tolerability and efficacy of motixafortide and G-CSF, compared to placebo and G-CSF, for the mobilization of HSCs for autologous transplantation in multiple myeloma patients. The primary objective of the study is to demonstrate that only one dose of motixafortide on top of G-CSF is superior to G-CSF alone in the ability to mobilize ≥ 6x106 CD34+ cells in up to two apheresis sessions. Secondary objectives include time to engraftment of neutrophils and platelets and durability of engraftment, as well as other efficacy and safety parameters.

    About BioLineRx

    BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

    The Company's lead program, motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with MSD. Motixafortide is also being evaluated in a Phase 2b study in consolidation AML and a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation.

    BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

    For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on FacebookTwitter, and LinkedIn.

    Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates; BioLineRx's ability to establish and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; risks related to the coronavirus outbreak; and statements as to the impact of the political and security situation in Israel on BioLineRx's business. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2020. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

    Contact:

    Tim McCarthy

    LifeSci Advisors, LLC

    +1-212-915-2564

    or

    Moran Meir

    LifeSci Advisors, LLC

    +972-54-476-4945

     

    Cision View original content:http://www.prnewswire.com/news-releases/biolinerx-announces-positive-results-from-interim-analysis-of-genesis-phase-3-trial-of-motixafortide-bl-8040-in-stem-cell-mobilization-301163726.html

    SOURCE BioLineRx Ltd.

    View Full Article Hide Full Article
  5. TEL AVIV, Israel, Oct. 29, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be tested in combination with the anti-PD-1 cemiplimab (LIBTAYO®) and standard-of-care chemotherapy (gemcitabine and nab-paclitaxel) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).

    This investigator-initiated Phase 2 study, led by Columbia University, will initially enroll 10-12 PDAC patients, and will be expanded to a total of 40 patients following an evaluation of the initial 10-12 patients based on pre-defined criteria. The primary endpoint of the study is the overall…

    TEL AVIV, Israel, Oct. 29, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be tested in combination with the anti-PD-1 cemiplimab (LIBTAYO®) and standard-of-care chemotherapy (gemcitabine and nab-paclitaxel) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).

    This investigator-initiated Phase 2 study, led by Columbia University, will initially enroll 10-12 PDAC patients, and will be expanded to a total of 40 patients following an evaluation of the initial 10-12 patients based on pre-defined criteria. The primary endpoint of the study is the overall response rate (ORR). Secondary endpoints include safety and tolerability, progression free survival (PFS), duration of clinical benefit (DCR) and overall survival (OS). Data from the study is anticipated in mid-2022.

    "Chemotherapy is the current standard of care for patients with metastatic PDAC, however the rates of response and survival remain very low. In addition, although immunotherapy has resulted in a paradigm shift in the treatment of a number of solid tumors, trials with immune checkpoint blockade in PDAC have been disappointing," stated Dr. Gulam Manji, Assistant Professor of Medicine and Director of Pancreas Medical Oncology and Translational Research at Columbia University Vagelos College of Physicians and Surgeons, and lead investigator. "Over several years of pre-clinical research, we have found that combining a CXCR4 inhibitor with immunotherapy and chemotherapy shows promising results in a mouse model of pancreatic cancer. In this regard, Motixafortide, with its high affinity and long receptor occupancy, together with the encouraging preliminary results published from the COMBAT trial, makes it an attractive candidate for a combination therapy with anti-PD-1 and chemotherapy. We look forward to initiating the first clinical trial to treat patients in first-line metastatic PDAC with this promising treatment regimen."

    "We are excited to collaborate with Dr. Manji on this trial, which will further assess the utility of Motixafortide as the backbone of a potentially promising combination therapy in this challenging cancer indication," stated Philip Serlin, Chief Executive Officer of BioLineRx. "The results reported to date in our ongoing COMBAT-KEYNOTE-202 study, which is evaluating Motixafortide in combination with KEYTRUDA® and chemotherapy in second-line metastatic PDAC, demonstrate an encouraging anti-tumor effect when compared to historical data. We are hopeful that we can replicate these improved responses in this first-line study and look forward to data in mid-2022. This is yet another potentially value-creating milestone that further validates Motixafortide's potential ability to treat a range of cancers across all stages of disease."   

    About Motixafortide in Cancer Immunotherapy

    Motixafortide is targeting CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed in many human cancers including PDAC. CXCR4 plays a key role in tumor growth, invasion, angiogenesis, metastasis and therapeutic resistance, and CXCR4 overexpression has been shown to be correlated with poor prognosis.

    Motixafortide is a short synthetic peptide used as a platform for cancer immunotherapy with unique features allowing it to function as a best-in-class antagonist of CXCR4. It shows high-affinity, long receptor occupancy and acts as an inverse agonist.

    In a number of clinical and preclinical studies, Motixafortide has been shown to affect multiple modes of action in "cold" tumors, including immune cell trafficking, tumor infiltration by immune effector T cells, and reduction in immunosuppressive cells (such as MDSCs) within the tumor niche, turning "cold" tumors, such as pancreatic cancer, into "hot" (i.e., sensitizing them to immune checkpoint inhibitors and chemotherapy).

    About Pancreatic Cancer

    Pancreatic cancer has a low rate of early diagnosis and a poor prognosis. Its incidence rate in the US is estimated at 3.2% of new cancer cases. In 2018, approximately 450,000 individuals globally were diagnosed with this condition, 55,000 of them in the US; and the incidence of pancreatic cancer is expected to continue to increase. Symptoms are usually non-specific and as a result, pancreatic cancer is often not diagnosed until it reaches an advanced stage. Surgical resection does not offer adequate treatment since only 20% of patients have resectable tumors at the time of diagnosis. Even among patients who undergo resection for pancreatic cancer and have tumor-free margins, the five-year survival rate is only 10%-25%. The overall five-year survival rate among pancreatic cancer patients is 10%, which constitutes the highest mortality rate among solid tumor malignancies. The overall median survival is less than one year from diagnosis, highlighting the need for the development of new therapeutic options.

    Despite advances in chemotherapeutics and immunotherapy, increases in median and overall survival rates in pancreatic cancer have been modest. Pancreatic cancer remains an area of unmet medical need, with no new approved therapies since the approval of nab-paclitaxel (Abraxane®) in combination with gemcitabine for first-line treatment in 2013 and Onivyde® in combination with fluorouracil and leucovorin for second-line treatment in 2015. The limited clinical benefits demonstrated by these existing standard treatment options reinforce the need for additional approaches.

    About BioLineRx

    BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

    The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with MSD. Motixafortide is also being evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation and a Phase 2b study in consolidation AML.

    BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

    For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on FacebookTwitter, and LinkedIn.

    Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates; BioLineRx's ability to establish and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; risks related to the coronavirus outbreak; and statements as to the impact of the political and security situation in Israel on BioLineRx's business. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2020. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

    Contact: 

    Tim McCarthy 

    LifeSci Advisors, LLC  

    +1-212-915-2564  

    or

    Moran Meir 

    LifeSci Advisors, LLC 

    +972-54-476-4945  

     

    Cision View original content:http://www.prnewswire.com/news-releases/biolinerx-announces-initiation-of-phase-2-clinical-trial-in-first-line-metastatic-pancreatic-cancer-301162941.html

    SOURCE BioLineRx Ltd.

    View Full Article Hide Full Article
View All BioLineRx Ltd. News